top of page
Personalized speech recognition models and other communication tools for pALS
Bob MacDonald is a Technical Program Manager focused on projects that apply AI techniques to solve problems related to disabilities and social good. This includes improving speech recognition for those with impaired speech as well as driving innovation in other assistive technologies. His prior work at Google involved using AI to improve cancer diagnostics and to improve access to health vital signs. He also led teams developing next generation imaging systems used for products like Google Maps and StreetView.
ALS Therapies and Treatment Updates: Updates on PrimeC
Mr.Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics. Mr Alon Ben-Noon is a Life Science Executive who prior to the establishment of NeuroSense, founded MediCan Consulting, a successful consultancy firm with clients from diversified biotech companies, and mainly in the neurodegenerative space. MediCan excelled at executing efficient, accurate, and innovative drug development programs for its clients. Prior to that, Alon worked at Teva and Perrigo. Join ALS research www.everythingals.org/research
30 years of ALS Genetics: distinguishing Signal from Noise
Dr. Matthew Harms is an Associate Professor of Neurology. He received his medical doctorate from the University of California San Francisco. Dr. Harms completed neuromuscular medicine and clinical neurophysiology fellowships at Washington University in St. Louis. His clinical training in neuromuscular diseases led him into the laboratory of Dr. Robert Baloh, where his post-doctoral research identified the genes responsible for two orphan human diseases- dominant spinal muscular atrophy with lower extremity predominance and limb-girdle muscular dystrophy type 1D. Dr. Harms joined the neuromuscular medicine faculty at Washington University in 2009 with board certifications in neurology, clinical neurophysiology, and neuromuscular medicine. In 2011, Dr. Harms assumed leadership of the Washington University Neuromuscular Genetics Project and established his research laboratory to continue harnessing emerging genetic technologies to understand the causes of inherited neuromuscular diseases. The lab focuses on diseases of the motor neuron, including ALS, and where his efforts have helped identify more than 5 novel disease genes. At Columbia, Dr. Harms continues these efforts, directing an international multi-site effort using whole genome and transcriptome sequencing to bring precision medicine to ALS. His laboratory efforts will occur in both the Motor Neuron Center and the Institute for Genomic Medicine.
Gene-environment interactions leading to ALS
Dr. Johnathan Cooper-Knock is an NIHR clinical lecturer in the department of neuroscience at the University of Sheffield. He studied medicine at the University of Oxford where he obtained a 1st Class Honors degree in Physiological Sciences and completed a degree in Clinical Medicine graduating in 2006. In 2008, Dr. Cooper-Knock was awarded a NIHR Academic Clinical Fellowship in Sheffield. He continued research initially as a Peake Start-Up fellow before being awarded a Lady Edith Wolfson Clinical Research Training Fellowship funded by the MNDA/MRC which facilitated the award of a PhD by publication in 2015. In 2017, he was awarded the European Network for Cure of ALS (ENCALS) Young Investigator Award.
ALS and Neurodegeneration Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia
Dr. Rothstein is Professor of Neurology and Neuroscience and a faculty member of the Graduate Program in Cellular and Molecular Medicine at Johns Hopkins University. He is the Founder and Director of the Robert Packard Center for ALS Research at Johns Hopkins. He is also the Director of the Brain Science Institute. He is also the Founder and Co-Director of the Johns Hopkins MDA/ALS Clinic. His team oversees one of the largest ALS clinics in the USA. Dr. Rothstein’s career has been highly focused on the identification of biological pathways that underlie and contribute to neuro-degeneration in ALS and the development of model systems to identify, test and validate therapies. These efforts began in the early 1990’ when his lab first discovered that excitotoxicity and mishandling of neurotransmitter glutamate might be a common pathophysiological process in sporadic ALS. This new concept and his experiments ultimately were the rationale for and use of riluzole ALS patients and its FDA approval. His research always employs a parallel analysis of model systems (e.g. mouse or human CNS cultures) and human tissues – as a validation of the relevance to real ALS. More recently, with the discovery of the C9orf72 gene mutation, his lab in collaboration with Ionis pharma, discovered the development of antisense oligonucleotides therapy for C9 ALS/FTD patients, and later, in collaboration with others, biomarkers that would be used to validate therapeutic target engagement in actual patients. In parallel with his drug discovery efforts, his lab has repeatedly made the discoveries on fundamental pathways that underlay familial and sporadic ALS including: excitotoxicity, astroglial dysfunction, oligodendroglial dysfunction and most recently, the role of nuclear pore complex and nucleocytoplasmic transport as one of the earliest pathophysiological event in familial ALS and likely sporadic ALS cases. Finally, aside from the many clinician scientists and basic scientists he has trained, he developed the Robert Packard Center for ALS research in 2000 as a model organization of mandatory academic collaboration and data sharing, the development of preclinical models and the free exchange of cutting edge ALS research. Recently he developed and founded the Answer ALS program - the world’s largest most comprehensive biological program to understand sporadic ALS and to be the starting point for “personalized medicine “ approach to ALS. The Answer ALS program is tasked with longitudinal clinical data and at home smartphone data collection and the generation of iPS neurons from each patient, and their comprehensive biological analytics- leading to a data set of 6 billion biological and clinical data points per patient. His program freely shares this enormous data collection to academic and companies worldwide.
New breakthroughs with NURO's second generation neurotechnologies
With a 30-year career as a Founder and CEO in Enterprise Technology and Biotechnology, Francois has a track record with thousands of complex projects delivered for some of the largest brands in the World. After a traumatic accident and the prior passing of his parents, his mother by a brain surgery and his father by Alzheimer’s, Francois decided to devote his expertise to complex care patients. From 2014 onward, his love for pushing technology to the next level translated into the creation of NURO and three major non-invasive neurotechnologies to date which have now changed the lives of incapacitated individuals across several continents. With NURO, Francois brings together progressive deliveries on applied neuroscience, computing and biotechnology for the benefit and advancement of mankind. Originally from France, Francois spent his childhood in the beautiful French Alps and then went on to study in Massachusetts and in Florida. He eventually moved to the Waterloo Region of Ontario, Canada, also known as the Silicon Valley of the North. He is a lover of technology, nature, music, extreme sports and has a particular interest in creating innovation when others believe it is impossible.
bottom of page